Skip to main content

Cancer Epigenetics - Solid Tumors

Section information

Section Editors : Maria Berdasco and Carmen Jeronimo 

Associate Editors : Nita Ahuja, Tiziana Bonaldi (histones), Rene Cortese, James Flanagan (cervical/ovarian), Mario Fraga, Michéle Hoffmann (prostate), Bozena Kaminska (gliomas), Gwen Lomberk, Arpad Patai (colorectal/GI cancers), Qian Tao, Raul Urrutia, Stefan Wiemann (breast), Keishi Yamashita

The development of genome-wide techniques has rapidly improved the comprehensive knowledge of epigenetic alterations in cancer. Currently, a vast number of genes and their associated molecular pathways that show epigenetic differences between normal and tumoral cells have been identified, emphasizing the crucial role of epigenetic factors in cancer etiology and progression.  This section publishes original epigenetic research focused on the identification of epigenetic biomarkers associated with cancer diagnosis or tumor progression. Manuscripts on epigenetic biomarkers leading to a better definition of therapy response are also accepted (pharmacoepigenetics). Submissions on reports from human clinical trials providing insights on the clinical application of epigenetic biomarkers are welcomed.

Page 8 of 8

  1. Pancreatic ductal adenocarcinoma (PDAC) remains a highly chemoresistant tumor entity for which no reliable molecular targets exist to predict or influence the success of chemotherapy. Recently, we identified a...

    Authors: Sameer Abdallah Dhayat, Baha Abdeen, Gabriele Köhler, Norbert Senninger, Jörg Haier and Wolf Arif Mardin
    Citation: Clinical Epigenetics 2015 7:132
  2. Aberrant DNA methylation has been widely investigated in sporadic colorectal carcinomas (CRCs), and extensive work has been performed to characterize different methylation profiles of CRC. Less information is ...

    Authors: Nora Sahnane, Francesca Magnoli, Barbara Bernasconi, Maria Grazia Tibiletti, Chiara Romualdi, Monica Pedroni, Maurizio Ponz de Leon, Giulia Magnani, Luca Reggiani-Bonetti, Lucio Bertario, Stefano Signoroni, Carlo Capella, Fausto Sessa and Daniela Furlan
    Citation: Clinical Epigenetics 2015 7:131
  3. Primary pulmonary enteric adenocarcinoma (PEAC) is defined as a pulmonary adenocarcinoma with a predominant component of intestinal differentiation and tumor cells positive for at least one intestinal marker. ...

    Authors: Ingrid Garajová, Niccola Funel, Michelangelo Fiorentino, Valentina Agostini, Manuela Ferracin, Massimo Negrini, Giovanni Luca Frassineti, Giampaolo Gavelli, Adam Enver Frampton, Guido Biasco and Elisa Giovannetti
    Citation: Clinical Epigenetics 2015 7:129
  4. About half of all prostate cancers harbor the TMPRSS2:ERG (T2E) gene fusion. While T2E-positive and T2E-negative tumors represent specific molecular subtypes of prostate cancer (PCa), previous studies have not ye...

    Authors: Milan S. Geybels, Joshi J. Alumkal, Manuel Luedeke, Antje Rinckleb, Shanshan Zhao, Irene M. Shui, Marina Bibikova, Brandy Klotzle, Piet A. van den Brandt, Elaine A. Ostrander, Jian-Bing Fan, Ziding Feng, Christiane Maier and Janet L. Stanford
    Citation: Clinical Epigenetics 2015 7:128
  5. While recent integrative analyses of copy number and gene expression data in breast cancer have revealed a complex molecular landscape with multiple subtypes and many oncogenic/tumour suppressor driver events,...

    Authors: Yang Gao, Allison Jones, Peter A. Fasching, Matthias Ruebner, Matthias W. Beckmann, Martin Widschwendter and Andrew E. Teschendorff
    Citation: Clinical Epigenetics 2015 7:126

    The Erratum to this article has been published in Clinical Epigenetics 2016 8:63

  6. There are currently no screening tests in routine use for oral and pharyngeal cancer beyond visual inspection and palpation, which are provided on an opportunistic basis, indicating a need for development of n...

    Authors: Scott M. Langevin, Melissa Eliot, Rondi A. Butler, Agnes Cheong, Xiang Zhang, Michael D. McClean, Devin C. Koestler and Karl T. Kelsey
    Citation: Clinical Epigenetics 2015 7:125
  7. ADAMTS19 encodes a member of the ADAMTS (a disintegrin and metalloproteinase domain with thrombospondin motifs) protein family with emerging roles in carcinogenesis and metastasis. ADA...

    Authors: Sergio Alonso, Beatriz González, Tatiana Ruiz-Larroya, Mercedes Durán Domínguez, Takaharu Kato, Akihiro Matsunaga, Koichi Suzuki, Alex Y. Strongin, Pepita Gimènez-Bonafé and Manuel Perucho
    Citation: Clinical Epigenetics 2015 7:124
  8. The Response Evaluation Criteria in Solid Tumors (RECIST) guideline and Common Terminology Criteria for Adverse Events (CTCAE) criteria are used to assess chemotherapy efficiency and toxicity in patients with ...

    Authors: Hong Wang, Bingfeng Zhang, Dan Chen, Wenying Xia, Jiexin Zhang, Fang Wang, Jian Xu, Yan Zhang, Meijuan Zhang, Lixia Zhang, Yachun Lu, Yan Geng, Peijun Huang, Puwen Huang, Hong Wang and Shiyang Pan
    Citation: Clinical Epigenetics 2015 7:119
  9. Multiple sclerosis (MS) is thought to be a T cell-mediated autoimmune disorder. MS pathogenesis is likely due to a genetic predisposition triggered by a variety of environmental factors. Epigenetics, particula...

    Authors: Vicki E. Maltby, Moira C. Graves, Rodney A. Lea, Miles C. Benton, Katherine A. Sanders, Lotti Tajouri, Rodney J. Scott and Jeannette Lechner-Scott
    Citation: Clinical Epigenetics 2015 7:118
  10. Epigenetic aberrations play a central role in the pathophysiology of acute myeloid leukemia (AML). It has been shown that molecular signatures based on DNA-methylation (DNAm) patterns can be used for classific...

    Authors: Tanja Božić, Qiong Lin, Joana Frobel, Stefan Wilop, Melanie Hoffmann, Carsten Müller-Tidow, Tim H. Brümmendorf, Edgar Jost and Wolfgang Wagner
    Citation: Clinical Epigenetics 2015 7:116
  11. Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological fea...

    Authors: Siri H. Strand, Soren Hoyer, Anne-Sofie Lynnerup, Christa Haldrup, Tine Maj Storebjerg, Michael Borre, Torben F. Orntoft and Karina D. Sorensen
    Citation: Clinical Epigenetics 2015 7:111
  12. Aberrant DNA methylation at imprinted loci is an important molecular mechanism contributing to several developmental and pathological disorders including cancer. However, knowledge about imprinting defects due...

    Authors: Sumadi Lukman Anwar, Till Krech, Britta Hasemeier, Elisa Schipper, Nora Schweitzer, Arndt Vogel, Hans Kreipe and Ulrich Lehmann
    Citation: Clinical Epigenetics 2015 7:110
  13. Long non-coding RNAs (lncRNAs) have been claimed as key molecular players in gene expression regulation, being involved in diverse epigenetic processes. They are aberrantly expressed in various tumors, but the...

    Authors: Mónica Martínez-Fernández, Andrew Feber, Marta Dueñas, Cristina Segovia, Carolina Rubio, Maria Fernandez, Felipe Villacampa, José Duarte, Fernando F. López-Calderón, Ma José Gómez-Rodriguez, Daniel Castellano, Jose L. Rodriguez-Peralto, Federico de la Rosa, Stephan Beck and Jesús M. Paramio
    Citation: Clinical Epigenetics 2015 7:109
  14. Subtelomeric regions dynamically change their epigenetic pattern during development and progression of several malignancies and degenerative disorders. However, DNA methylation of human subtelomeres and their ...

    Authors: Samrat Roy Choudhury, Yi Cui, Jacob R. Milton, Jian Li and Joseph Irudayaraj
    Citation: Clinical Epigenetics 2015 7:107
  15. To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and ther...

    Authors: Monika Bauden, Dorian Pamart, Daniel Ansari, Marielle Herzog, Mark Eccleston, Jake Micallef, Bodil Andersson and Roland Andersson
    Citation: Clinical Epigenetics 2015 7:106
  16. CpG hypermethylation in gene promoters is a frequent mechanism of tumor suppressor gene silencing in various types of cancers. It usually occurs at early steps of cancer progression and can be detected easily,...

    Authors: Nilufer Sayar, Gurbet Karahan, Ozlen Konu, Betul Bozkurt, Onder Bozdogan and Isik G. Yulug
    Citation: Clinical Epigenetics 2015 7:104
  17. Serrated adenocarcinoma (SAC) is a recently recognized colorectal cancer (CRC) subtype accounting for 7.5–8.7 % of CRCs. It has been shown that SAC has a worse prognosis and different histological and molecula...

    Authors: Pablo Conesa-Zamora, José García-Solano, María del Carmen Turpin, Patricia Sebastián-León, Daniel Torres-Moreno, Eduardo Estrada, Anne Tuomisto, Jamie Wilce, Markus J. Mäkinen, Miguel Pérez-Guillermo and Ana Conesa
    Citation: Clinical Epigenetics 2015 7:101
  18. Altered DNA methylation of imprinted genes has been implicated in a range of cancers. Imprinting is established early in development, and some are maintained throughout the life course in multiple tissues, pro...

    Authors: Kristina Harrison, Gwen Hoad, Paula Scott, Louise Simpson, Graham W. Horgan, Elizabeth Smyth, Steven D. Heys and Paul Haggarty
    Citation: Clinical Epigenetics 2015 7:92
  19. DNA methylation (5-methylcytosine (5mC)) patterns are often altered in cancers. Ten-eleven translocation (Tet) proteins oxidise 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytos...

    Authors: Maria Eleftheriou, Ana Jimenez Pascual, Lee M. Wheldon, Christina Perry, Abdulkadir Abakir, Arvind Arora, Andrew D. Johnson, Dorothee T. Auer, Ian O. Ellis, Srinivasan Madhusudan and Alexey Ruzov
    Citation: Clinical Epigenetics 2015 7:88
  20. Insufficient specificity of the high-risk human papillomavirus (hrHPV) assay in primary cervical cancer screening results in unnecessary referral. Additional assays to triage hrHPV-positive women are needed to...

    Authors: Par Bahadur Pun, Yu-Ping Liao, Po-Hsuan Su, Hui-Chen Wang, Yu-Chih Chen, Yaw-Wen Hsu, Rui-Lan Huang, Cheng-Chang Chang and Hung-Cheng Lai
    Citation: Clinical Epigenetics 2015 7:85
  21. Many cancers show aberrant silencing of gene expression and overexpression of histone methyltransferases. The histone methyltransferases (HKMT) EZH2 and EHMT2 maintain the repressive chromatin histone methylat...

    Authors: Edward Curry, Ian Green, Nadine Chapman-Rothe, Elham Shamsaei, Sarah Kandil, Fanny L Cherblanc, Luke Payne, Emma Bell, Thota Ganesh, Nitipol Srimongkolpithak, Joachim Caron, Fengling Li, Anthony G. Uren, James P. Snyder, Masoud Vedadi, Matthew J. Fuchter…
    Citation: Clinical Epigenetics 2015 7:84
  22. Lynch syndrome (LS) is associated with germline mutations in DNA mismatch repair (MMR) genes. The first “hit” to inactivate one allele of the predisposing MMR gene is present in every cell, contributing to acc...

    Authors: Satu Valo, Sippy Kaur, Ari Ristimäki, Laura Renkonen-Sinisalo, Heikki Järvinen, Jukka-Pekka Mecklin, Minna Nyström and Päivi Peltomäki
    Citation: Clinical Epigenetics 2015 7:71
  23. Classification of pediatric tumors into biologically defined subtypes is challenging, and multifaceted approaches are needed. For this aim, we developed a diagnostic classifier based on DNA methylation profiles.

    Authors: Anna Danielsson, Szilárd Nemes, Magnus Tisell, Birgitta Lannering, Claes Nordborg, Magnus Sabel and Helena Carén
    Citation: Clinical Epigenetics 2015 7:62
  24. An important model of hepatocellular carcinoma (HCC) that has been described in southeast Asia includes the transition from chronic hepatitis B infection (CHB) to liver cirrhosis (LC) and, finally, to HCC. The...

    Authors: Yangxing Zhao, Feng Xue, Jinfeng Sun, Shicheng Guo, Hongyu Zhang, Bijun Qiu, Junfeng Geng, Jun Gu, Xiaoyu Zhou, Wei Wang, Zhenfeng Zhang, Ning Tang, Yinghua He, Jian Yu and Qiang Xia
    Citation: Clinical Epigenetics 2014 6:30